Advertisement
Advertisement
U.S. Markets open in 6 hrs 33 mins
S&P Futures
3,991.25 -28.50 (-0.71%) Dow Futures
31,944.00 -176.00 (-0.55%) Nasdaq Futures
12,281.00 -101.75 (-0.82%) Russell 2000 Futures
1,775.70 -13.80 (-0.77%) Crude Oil
109.30 -1.19 (-1.08%) Gold
1,803.70 -4.50 (-0.25%)
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 194.32 |
| Open | 196.93 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1100 |
| Day's Range | 196.25 - 200.27 |
| 52 Week Range | 187.16 - 468.55 |
| Volume | |
| Avg. Volume | 1,124,733 |
| Market Cap | 29.248B |
| Beta (5Y Monthly) | 0.44 |
| PE Ratio (TTM) | 19.49 |
| EPS (TTM) | 10.22 |
| Earnings Date | Apr 20, 2022 - Apr 25, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 317.17 |
- News Direct
Biogen's Alex Cameron Discusses Biogen-MIT Biotech in Action
When the pandemic hit, in-person lessons at the Community Lab paused. That’s when Biogen-Lemelson-MIT Program Biotech in Action launched, providing online science and lab classes. Going virtual all...
- American City Business Journals
The Petri Dish: Biogen seeks accelerated approval for second Alzheimer's drug
Biogen and development partner Eisai are looking to get their next Alzheimer's drug to market using the FDA's accelerated approval pathway.
- Investor's Business Daily
Biogen Pops After Eisai Asks FDA To Approve A New Alzheimer's Treatment
Biogen stock popped Tuesday after the company's partner, Eisai, finished submitting its application for an experimental Alzheimer's drug.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
